Endovia raises equity line commitment to $135 million from $35 million
Endovia Health Sciences entered into an addendum on October 22, 2026, to its equity line of credit with C/M Capital Master Fund, LP, raising the total maximum commitment from $35 million to $135 million, including prior sales. The addendum also sets updated terms for sales made beyond the initial 10,875,000 shares already sold and issued under the agreement, which affects how much new common stock the company may issue over time.
Key points
- Addendum dated October 22, 2026, amends the Securities Purchase Agreement dated September 19, 2025, with C/M Capital Master Fund, LP
- Total maximum commitment increases from $35 million to $135 million, inclusive of prior sales
- Updated terms apply to sales above the initial 10,875,000 shares sold and issued under the agreement
- Original agreement was filed as Exhibit 10.3 to a Form 8-K on September 25, 2025
The filing
Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 27, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.